Tenet Healthcare (NYSE: THC) Director Nadja West sold 1,152 shares of common stock on September 2, 2026, according to a recently disclosed SEC Form 4 filing.
The transaction was executed at a weighted average sale price of $258.80 per share, generating total proceeds of approximately $298,138 for the director.
The shares sold represented 5% of West’s directly held equity position prior to the transaction, a relatively modest portion of her overall stake in the company.
Following the sale, West retains a direct holding of 23,653 shares, valued at approximately $6.1 million based on the September 2, 2026, market close price of $258.53.
Analysts and investors typically scrutinize insider sales for signals about executive sentiment, but the size and context of this transaction suggest it is largely routine in nature.
Tenet Healthcare operates across three primary divisions, including Hospital Operations and Other, Ambulatory Care, and Conifer, delivering integrated healthcare services across inpatient, outpatient, and ancillary care settings.
The company’s network of acute care facilities generates revenue through emergency services, surgical procedures, diagnostic imaging, clinical laboratory services, and on-site pharmacy operations.
Tenet serves insured individuals, government-sponsored program beneficiaries, and self-pay patients, positioning itself as a broad-based healthcare provider across multiple geographic markets.
With 77,000 employees, trailing twelve-month revenue of $21.8 billion, and net income of $2.2 billion, Tenet ranks among the largest healthcare facility operators in the United States.
THC shares have climbed 37.7% over the past year, significantly outpacing the S&P 500’s 14.8% return over the same period, providing context for why an executive might trim a small portion of holdings.
The company’s market capitalization stands at $21.1 billion, reflecting investor confidence in Tenet’s diversified operational structure and strong profitability across its multi-divisional business model.
Of the 24 analysts who cover Tenet Healthcare, 83% rate the stock a buy, while the remaining 17% rate it a hold, indicating broadly favorable sentiment toward the company’s outlook.
The median one-year analyst price target sits at $284, which would represent a gain of approximately 8.4% from the September 19, 2026, price of $261.99.
Given the strong stock price performance over the past year, this insider sale appears unlikely to raise significant concerns among shareholders monitoring THC’s trajectory.
